A novel combination HIV prevention strategy: Post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine- using men who have sex with men

AIDS Patient Care and STDs

Volumn 26, Issue 6, 2012, Pages 320-328

  Landovitz, Raphael J ^a   Fletcher, Jesse B ^b   Inzhakova, Galina ^b   Lake, Jordan E ^a   Shoptaw, Steven ^c   Reback, Cathy J ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FRIENDS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; METHAMPHETAMINE;

ADULT; ARTICLE; CHLAMYDIASIS; DEPRESSION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PILOT STUDY; POST EXPOSURE PROPHYLAXIS; SEROCONVERSION; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SYNCOPE; SYPHILIS; TREATMENT DURATION;

ADULT; AMPHETAMINE-RELATED DISORDERS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INTERVENTION STUDIES; MALE; MEDICATION ADHERENCE; METHAMPHETAMINE; PILOT PROJECTS; POST-EXPOSURE PROPHYLAXIS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; UNSAFE SEX;

EID: 84862182237     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0432     Document Type: Article

References (52)

1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV Incidence in the United States. JAMA 2008;300:520-529.
2. Centers for Disease Control and Prevention. Prevalence and awareness of HIV infection among men who have sex with men-21 cities, United States, 2008.MMWR Morb Mortal Wkly Rep 2010 2010;59:1201-1207.
3. Plankey MW, Ostrow DG, Stall R, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2007;45:85-92. (Pubitemid 46684447)
4. Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: A model for guiding public policy. J Urban Health 2006; 83:1151-1157. (Pubitemid 46024892)
5. Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med 1998;168:93-97. (Pubitemid 28100967)
6. Purcell DW, Parsons JT, Halkitis PN, Mizuno Y, Woods WJ. Substance use and sexual transmission risk behavior of HIVpositive men who have sex with men. J Subst Abuse 2001;13:185-200. (Pubitemid 38209970)
7. Stall R, Paul JP, Greenwood G, et al. Alcohol use, drug use and alcohol related problems among men who have sex with men: the urban men's health study. . Addiction 2001;96:1589-1601.
8. Greenwood GL, White E, Page-Shafer K, et al. Correlates of heavy substance use among young gay and bisexual men: the San Francisco young men's health study. Drug Alcohol Depend 2000;61:105-112.
9. Buchacz K, McFarland W, Kellogg TA, et al. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS 2005; 19:1423-1424. (Pubitemid 41800679)
10. Colfax G, Coates TJ, Husnik MJ, et al. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. J Urban Health 2005;82(1 Suppl 1):i62-70. (Pubitemid 41442805)
11. Drumright L, Patterson T, Strathdee S. Club drugs as casual risk factors for HIV acquisition among men who have sex with men: a review. Subst Use Misuse 2006;41:1551-1601. (Pubitemid 44470231)
12. Garofalo R, Mustanski BS, McKirnan DJ, Jerrick A, Donenberg GR. Methamphetamine and young men who have sex with men: Understanding patterns and correlates of use and the association with HIV-related sexual risk. Arch Pediatr Adolesc Med 2007;161:591-596. (Pubitemid 46878685)
13. Shoptaw S, Peck JA, Reback CJ, Rotheram-Fuller E. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment. J Psychoactive Drugs 2003;35 (Suppl 1):161-168. (Pubitemid 36676106)
14. HIV Epidemiology Program Los Angeles County Department of Public Health. 2010 Annual HIV Surveillance Report. 2011. http://publichealth.lacounty.gov/hiv/
15. Rajasingham R, Mimiaga MJ, White JM, Pinkston MM, Baden RP, Mitty JA. A systematic review of behavioral and treatment outcome studies among hiv-infected men who have sex with men who abuse crystal methamphetamine AIDS Patient Care STDS 2012;26:36-52.
16. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;337:1485-1490. (Pubitemid 27495773)
17. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, Cheever L, Johnson M, Paxton LA, Onorato IM, Greenberg AE. Antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV in the United States: Recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005;54:1-20.
18. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-1199.
19. Wade NA, Zielinski MA, Butsashvili M, et al. Decline in perinatal HIV transmission in New York State (1997-2000). J Acquir Immune Defic Syndr 2004;36:1075-1082. (Pubitemid 38989374)
20. Roland ME, Neilands TB, Krone MR, et al. Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV. Clin Infect Dis 2005;41:1507-1513. (Pubitemid 41579997)
21. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-4273. (Pubitemid 28188732)
22. Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 2006;11:185-194.
23. Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patient with substance abuse issues. Clin Infect Dis 2007;45(Suppl 4):S318-S323. (Pubitemid 351417236)
24. Ellis RJ, Childers ME, Cherner M, et al. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003;188:1820-1826. (Pubitemid 38064866)
25. Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 2003;15:775-785. (Pubitemid 37494567)
26. Patrick G OC. HIV post-exposure therapy for drug users in treatment. J Subst Abuse Treat 2000;18:17-21.
27. Eaton L. A., Kalichman S. Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007;4:165-172.
28. Abbas U, Anderson R, Mellors JW. Potential effect of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007;2:e875.
29. Schechter M., do Lago R. F., Mendelsohn A. B., Moreira R. L., Moulton L. H., Harrison L. H. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acqir Immune Defic Syndr 2004 2004;35:519-525. (Pubitemid 38420661)
30. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004;18:787-792. (Pubitemid 38535007)
31. Donnell D, Mimiaga M, Mayer K, Chesney M, Koblin B, Coates T. Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial. AIDS Behav 2010;14:1182-1189.
32. Scott JD, Bolan RK. Factors associated with poor follow-up to hiv post-exposure prophylaxis [Abstract 71]. 2nd International Workshop on HIV Transmission. Washington, DC; 2007.
33. Schepis TS, Duhig AM, Liss T, et al. Contingency management for smoking cessation: Enhancing feasibility through use of immunoassay test strips measuring cotinine. Nicotine Tob Res 2008;10:1495-1501.
34. Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G. Financial incentive-based approaches for weight loss: a randomized trial. JAMA 2008;300:2631-2637.
35. Volpp KG, Loewenstein G, Troxel AB, et al. A test of financial incentives to improve warfarin adherence. BMC Health Serv Res 2008;8:272.
36. Volpp KG, Troxel AB, Pauly MV, et al. A randomized, controlled trial of financial incentives for smoking cessation. New Engl J Med 2009;360:699-709.
37. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction 2006;101:267-274. (Pubitemid 43351600)
38. Rawson RA, Huber A, McCann M, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry 2002;59:817-824. (Pubitemid 35001147)
39. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIVrelated sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend 2005;78:125-134. (Pubitemid 40544599)
40. Reback CJ, Peck JA, Dierst-Davies R, Nuno M, Kamien JB, Amass L. Contingency management among homeless, outof-treatment men who have sex with men. J Subst Abuse Treat 2010;39:255-263.
41. Hanson T, Alessi SM, Petry NM. Contingency management reduces drug-related human immunodeficiency virus risk behaviors in cocaine-abusing methadone patients. Addiction 2008;103:1187-1197. (Pubitemid 351843401)
42. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993;150:763-769. (Pubitemid 23137683)
43. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994;51:568-576. (Pubitemid 24211034)
44. Higgins ST, Delaney DD, Budney AJ, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 1991;148:1218-1224.
45. Reback CJ, Shoptaw S. Development of an evidence-based, gay-specific cognitive behavioral therapy intervention for methamphetamine-abusing gay and bisexual men. Addict Behav. 2011;epub ahead of print November 25, 2011.
46. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409-1414. (Pubitemid 28516063)
47. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP Study. J Infect Dis 2001;183:707-714. (Pubitemid 32171744)
48. Sonder GJ, Prins JM, Regez RM, et al. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in amsterdam: adverse effects do not influence compliance. Sex Transm Dis 2010;37:681-686.
49. Reback CJ, Peck JA, Dierst-Davies R, Nuno M, Kamien JB, Amass A. Contingency management among homeless, outof-treatment men who have sex with men. J Subst Abuse Treat. 2010;39:255-263.
50. Prochaska JO, DiClemente CC. The Transtheoretical Approach: Crossing Traditional Boundaries of Therapy. Homewood IL: Dow Jones-Irwin 1984.
51. Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: A network explanation. Sex Transm Dis 1999;26:250-261.
52. Garnett GP. The transmission dynamics of sexually transmitted diseases. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually Transmitted Diseases, 4th ed. New York: McGraw Hill Professional; 2008:27-39.